Pfizer, Inc. (NYSE:PFE)‘s stock had its “buy” rating restated by BMO Capital Markets in a research note issued on Thursday. They presently have a $37.00 price objective on the biopharmaceutical company’s stock. BMO Capital Markets’ price target points to a potential upside of 5.53% from the company’s previous close.

PFE has been the topic of a number of other research reports. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research note on Monday, July 10th. Finally, UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research note on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $37.72.

Pfizer (PFE) opened at 35.06 on Thursday. The firm’s 50-day moving average is $33.44 and its 200-day moving average is $33.49. The stock has a market cap of $208.51 billion, a P/E ratio of 25.65 and a beta of 1.00. Pfizer has a 52-week low of $29.83 and a 52-week high of $35.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the company posted $0.64 earnings per share. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. Equities research analysts predict that Pfizer will post $2.56 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Pfizer, Inc. (PFE) Rating Reiterated by BMO Capital Markets” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/14/pfizer-inc-pfe-rating-reiterated-by-bmo-capital-markets.html.

In other news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the completion of the transaction, the insider now directly owns 74,506 shares of the company’s stock, valued at approximately $2,436,346.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 426,291 shares of company stock valued at $14,475,911. 0.06% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. W. E. Donoghue & Co. LLC acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $16,402,000. Intl Fcstone Inc. increased its holdings in Pfizer by 444.3% during the 2nd quarter. Intl Fcstone Inc. now owns 56,081 shares of the biopharmaceutical company’s stock valued at $1,884,000 after purchasing an additional 45,777 shares in the last quarter. M Holdings Securities Inc. increased its holdings in Pfizer by 41.5% during the 2nd quarter. M Holdings Securities Inc. now owns 26,036 shares of the biopharmaceutical company’s stock valued at $875,000 after purchasing an additional 7,635 shares in the last quarter. Griffin Asset Management Inc. acquired a new stake in Pfizer during the 2nd quarter valued at $768,000. Finally, Farmers National Bank increased its holdings in Pfizer by 3.2% during the 2nd quarter. Farmers National Bank now owns 107,106 shares of the biopharmaceutical company’s stock valued at $3,598,000 after purchasing an additional 3,352 shares in the last quarter. 69.09% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.